Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation.
about
Immunologic considerations in heart transplantation for congenital heart diseaseSensitive solid-phase detection of donor-specific antibodies as an aid highly relevant to improving allograft outcomes.Aortic regurgitation: quantitative methods by echocardiography.Novel solid phase-based ELISA assays contribute to an improved detection of anti-HLA antibodies and to an increased reliability of pre- and post-transplant crossmatching.The sensitized pediatric heart transplant candidate: causes, consequences, and treatment options.Plasma Exchange and Immunoadsorption of Patients with Thoracic Organ Transplantation.Antibody-mediated rejection as a contributor to previously unexplained early liver allograft lossAnti-HLA alloantibodies in pediatric solid organ transplantation.Ventricular-assist devices for the treatment of chronic heart failure.HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP.Practical application of the virtual crossmatch.Immunogenicity of human embryonic stem cells.Occurrence of Fatal and Nonfatal Adverse Outcomes after Heart Transplantation in Patients with Pretransplant Noncytotoxic HLA Antibodies.Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes.The long-term outcome of treated sensitized patients who undergo heart transplantation.Antibody depletion for the treatment of crossmatch-positive pediatric heart transplant recipients.Report from a consensus conference on the sensitized patient awaiting heart transplantationHeart transplantation in adults with end-stage congenital heart disease.Cardiac antibody-mediated rejection.Reduced MHC alloimmunization and partial tolerance protection with pathogen reduction of whole blood.Clinical outcomes in sensitized heart transplant patients bridged with ventricular assist devices.B cells help alloreactive T cells differentiate into memory T cells.Rapamycin as rescue therapy in a patient supported by biventricular assist device to heart transplantation with consecutive ongoing rejection.Reduced alloimmunization in mice following repeated transfusion with pathogen-reduced platelets.C1q-binding anti-HLA antibodies do not predict platelet transfusion failure in Trial to Reduce Alloimmunization to Platelets study participants.The role of complement-fixing donor-specific antibodies identified by a C1q assay after heart transplantation.Platelet transfusions are not associated with increased morbidity or mortality in cardiac surgery.Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after heart transplantation.Increased alloreactive and autoreactive antihuman leucocyte antigen antibodies associated with systemic lupus erythematosus and rheumatoid arthritis
P2860
Q26995790-C2B4003F-B0C7-413A-B8FA-BBD578F8431EQ30317554-48645FDC-08DD-4302-B0F5-9CFFF9148145Q34026416-6511CE77-18CF-435A-81B3-F588E2160AABQ35574072-933E1437-85D0-4ECF-9F8F-28449483186AQ36078701-AECB873A-F924-4006-8AA4-8C6773F472DCQ36210336-2F1DCBBD-A298-43E1-ADEA-5C60952DB990Q36216606-BB961E83-8BC4-41CF-A35F-182EB9EB6C5FQ36435828-45E2369E-014C-444D-8804-05E828E116F4Q36815993-FDDFDB9F-9E77-44DC-943D-A61ECA422548Q36858319-50841FAB-C43B-46C2-8EEF-F358FE2F1886Q36896650-23AFEAC8-B160-4219-88F7-B9AF632AF442Q36936814-EA7F60EF-4298-49A1-9B28-80400AA935E1Q37101254-79CBCF2C-E23F-4B9A-B8D8-9BFFF16F247FQ37300446-3981E83B-BA96-4B6E-9BA3-846D4DB026A9Q37313073-C423BC83-D3F6-4C78-8B98-C8E8974B6B0FQ37350033-AFCEA24B-110F-4CC0-A319-DA655527EEC9Q37414657-68691379-A2DB-4225-A88B-B37F4AE7E95EQ37993155-4E75843D-36D4-4F8E-9007-F01637BEF4C0Q38002449-FE3C0D1C-7E07-4220-A7FB-03D6E3AEB4F8Q38794017-901DEFFF-3B6F-4B15-9C74-344AA2455B21Q41429964-EA8DCC34-3097-495E-B1D9-9103EDE091BBQ42409134-5CF687C8-3B41-4D70-A57B-647513E27FCBQ44326136-2FD997B7-BC58-47B6-92D7-73C0C03521A9Q46513449-911CFDB3-00C4-4BDA-A9A6-B823666F7461Q46689029-F807BDB3-B47F-41E7-A434-75543912D193Q48305003-811A0F7D-CA07-477E-A76D-7699AF5D138AQ48716343-7368514E-CFB9-44C9-8928-6E83B3C35859Q52605034-6A32B677-D2F1-471F-A1D6-C6C120A4D732Q57299927-9377463E-867E-42F1-A027-01B560297D9E
P2860
Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Preformed IgG antibodies again ...... ents of heart transplantation.
@en
Preformed IgG antibodies again ...... ents of heart transplantation.
@nl
type
label
Preformed IgG antibodies again ...... ents of heart transplantation.
@en
Preformed IgG antibodies again ...... ents of heart transplantation.
@nl
prefLabel
Preformed IgG antibodies again ...... ents of heart transplantation.
@en
Preformed IgG antibodies again ...... ents of heart transplantation.
@nl
P2093
P356
P1433
P1476
Preformed IgG antibodies again ...... ents of heart transplantation.
@en
P2093
Michler RE
Suciu-Foca N
Weinberg A
P304
P356
10.1161/01.CIR.98.8.786
P407
P577
1998-08-01T00:00:00Z